Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.40
+0.92 (4.98%)
At close: Jul 2, 2026, 4:00 PM EDT
19.71
+0.31 (1.60%)
Pre-market: Jul 6, 2026, 5:49 AM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $141.00K in the quarter ending March 31, 2026, with 95.83% growth. This brings the company's revenue in the last twelve months to $912.00K, up 201.99% year-over-year. In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth.
Revenue (ttm)
$912.00K
Revenue Growth
+201.99%
P/S Ratio
30.21
Revenue / Employee
$281,421
Employees
252
Market Cap
2.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 899.11M |
| ADMA Biologics | 509.86M |
| Zai Lab | 453.28M |
| Agios Pharmaceuticals | 66.05M |
| Ocular Therapeutix | 52.04M |
| Monte Rosa Therapeutics | 42.95M |
| Stoke Therapeutics | 32.08M |
| Generate Biomedicines | 30.30M |
VRDN News
- 5 days ago - Viridian Therapeutics price target raised to $43 from $32 at Wedbush - TheFly
- 5 days ago - Viridian Therapeutics price target raised to $38 from $35 at Truist - TheFly
- 5 days ago - Viridian Therapeutics price target raised to $35 from $34 at RBC Capital - TheFly
- 5 days ago - Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs - TheFly
- 6 days ago - Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform - TheFly
- 6 days ago - Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo - TheFly
- 6 days ago - Viridian Therapeutics Transcript: FDA announcement - Transcripts
- 6 days ago - Viridian Therapeutics Press release: FDA announcement - Filings